Key result
Local antisense c-myc during PTCA cuts late luminal loss ~50% vs saline in rabbits.
Why the study?
Myointimal hyperplasia after PTCA is a key component of restenosis, and c-myc is a critical protein involved in neointima formation, motivating evaluation of local c-myc antisense oligonucleotide delivery.
Does local delivery of c-myc neutrally charged antisense oligonucleotides reduce myointimal hyperplasia after PTCA in a rabbit balloon injury model?
Does local delivery of c-myc neutrally charged antisense oligonucleotides reduce myointimal hyperplasia after PTCA in a rabbit balloon injury model?
Absolute Event Rate: 0.9% vs 1.8%
p-value: p=0.001
Local delivery of c-myc antisense oligonucleotides significantly reduces myointimal hyperplasia and late luminal loss following balloon angioplasty in a rabbit model.
Supports antisense c-myc for restenosis prevention; leaves open translation to human PTCA outcomes.
Myointimal hyperplasia after percutaneous transluminal coronary angioplasty (PTCA) is a key component of the process of restenosis. The c-myc is a critical cell-cycle division protein involved in the formation of neointima. We evaluated the long-term impact of local delivery of c-myc neutrally charged antisense oligonucleotides (Resten-NG) on myointimal hyperplasia after PTCA in a rabbit model. PTCA was performed in the iliac arteries of 25 New Zealand white rabbits, using a Transport catheter at 8 atm for 30 sec, three times; 500 microg Resten-NG (n = 11) or saline (n = 14) was delivered to the PTCA site at 2 atm with the outer balloon for 2 min. The diet was supplemented with 0.25% cholesterol for 10 days before and 60 days after PTCA. Angiography was performed at harvest, and vessels were fixed in formalin, processed, and stained with hematoxylin and eosin (H&E) and Movat. Quantitative angiography showed that local delivery of antisense c-myc at PTCA reduced late luminal loss from 1.8 +/- 0.30 mm in control animals to 0.90 +/- 0.30 mm in the treatment group (P = 0.001). Histological analysis by planimetry showed that intimal areas were 1.67 +/- 0.44 mm(2) and 0.82 +/- 0.32 mm(2) in the control and antisense delivery groups, respectively (P < 0.05). We conclude that local delivery of Resten-NG inhibited myointimal hyperplasia after PTCA in cholesterol-fed rabbits for up to 60 days.
No takes yet. Share an insight, caveat, or question.
Kipshidze et al. (2001) studied Myointimal hyperplasia after PTCA (n=25). c-myc neutrally charged antisense oligonucleotides (Resten-NG) vs. Saline was evaluated on Late luminal loss (p=0.001). Local delivery of antisense c-myc (Resten-NG) during PTCA significantly reduced late luminal loss compared to saline (0.90 vs 1.8 mm, P=0.001) in a rabbit balloon injury model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: